Overview
Paramyotonia congenita of Von Eulenburg (PMC) is a rare inherited skeletal muscle disorder belonging to the group of non-dystrophic myotonias caused by mutations in the SCN4A gene, which encodes the voltage-gated sodium channel Nav1.4 in skeletal muscle. The condition is characterized by myotonia (difficulty relaxing muscles after voluntary contraction) that is paradoxically worsened by repeated muscle use — hence the term 'paramyotonia,' which distinguishes it from classical myotonia where repeated contractions typically improve stiffness. A hallmark feature of PMC is that symptoms are prominently triggered or aggravated by cold exposure. The disease primarily affects skeletal muscles, with the face, hands, and forearms being most commonly involved. Patients may experience muscle stiffness, difficulty opening the eyes or releasing grip in cold environments, and episodes of muscle weakness that can follow prolonged myotonia or cold exposure. Symptoms are typically present from birth or early infancy and remain relatively stable throughout life, though they do not usually worsen progressively. During cold-induced episodes, patients may develop flaccid weakness lasting minutes to hours. The severity of symptoms varies among affected individuals, even within the same family. Electromyography (EMG) typically demonstrates myotonic discharges, and genetic testing of the SCN4A gene confirms the diagnosis. There is no cure for paramyotonia congenita, but treatment focuses on symptom management. Sodium channel blockers such as mexiletine are the primary pharmacological treatment and can effectively reduce myotonia in many patients. Avoidance of cold exposure and careful management of triggers are important non-pharmacological strategies. Other medications that have been used include lamotrigine, flecainide, and acetazolamide, though evidence is more limited. The condition does not typically affect life expectancy, and most patients maintain a good quality of life with appropriate management.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Paramyotonia congenita of Von Eulenburg.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Paramyotonia congenita of Von Eulenburg at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Paramyotonia congenita of Von Eulenburg.
Community
No community posts yet. Be the first to share your experience with Paramyotonia congenita of Von Eulenburg.
Start the conversation →Latest news about Paramyotonia congenita of Von Eulenburg
No recent news articles for Paramyotonia congenita of Von Eulenburg.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Paramyotonia congenita of Von Eulenburg
What is Paramyotonia congenita of Von Eulenburg?
Paramyotonia congenita of Von Eulenburg (PMC) is a rare inherited skeletal muscle disorder belonging to the group of non-dystrophic myotonias caused by mutations in the SCN4A gene, which encodes the voltage-gated sodium channel Nav1.4 in skeletal muscle. The condition is characterized by myotonia (difficulty relaxing muscles after voluntary contraction) that is paradoxically worsened by repeated muscle use — hence the term 'paramyotonia,' which distinguishes it from classical myotonia where repeated contractions typically improve stiffness. A hallmark feature of PMC is that symptoms are promin
How is Paramyotonia congenita of Von Eulenburg inherited?
Paramyotonia congenita of Von Eulenburg follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Paramyotonia congenita of Von Eulenburg typically begin?
Typical onset of Paramyotonia congenita of Von Eulenburg is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Paramyotonia congenita of Von Eulenburg?
7 specialists and care centers treating Paramyotonia congenita of Von Eulenburg are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.